Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03734692|
Recruitment Status : Recruiting
First Posted : November 8, 2018
Last Update Posted : December 3, 2019
AIM ImmunoTech Inc.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Robert Edwards, University of Pittsburgh
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Estimated Primary Completion Date :||February 20, 2021|
|Estimated Study Completion Date :||November 20, 2023|